Daihan Pharmaceutical Co.Ltd (023910) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Daihan Pharmaceutical Co.Ltd stock KRW 50,134, price KRW 24,700, upside +103.0%, quality 53 out of 100. Rating: strongly undervalued. Calculated from audited financials with 23 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range 22,138 KRW – 32,697 KRW · fair‑value band 31,969 KRW – 74,270 KRW · the 24,700 KRW price screens below the 50,134 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Daihan Pharmaceutical Co.Ltd in your weekly email
Every Wednesday you see whether Daihan Pharmaceutical Co.Ltd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Daihan Pharmaceutical Co.,Ltd. engages in the manufacture and sale of therapeutic drugs in South Korea. The company offers various drugs, such as prescription, OTC, and quasi drugs, as well as offers various infusion related solutions.
Show moreShow less
Daihan Pharmaceutical Co.,Ltd. was founded in 1945 and is headquartered in Seoul, South Korea.
Stock analysis
Daihan Pharmaceutical Co.Ltd (023910) currently trades at 24,700 KRW, while our model-based Fair Value estimate is 50,134 KRW, implying the stock looks roughly 51% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 88,782 KRW per share, and 17 of the 23 models we run sit above the 24,700 KRW price.
Bear case: the Growth DCF group reads lowest at 8,405 KRW, and 6 of the 23 models stay below the price. Data coverage for this calculation is high.
Scenario range: 31,969 KRW (bear) to 74,270 KRW (bull), the price of 24,700 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Daihan Pharmaceutical Co.Ltd reported revenue of 209B KRW in FY2025 versus 171B KRW in FY2021, a compound +5.0%/yr. Reported net income was 27.6B KRW in FY2025, compounding +5.1%/yr from FY2021.
Key figures
Market cap 145B KRW (≈ $107M) Micro · P/E ratio 5.3 · P/S ratio 0.67 · EPS (TTM) 4,682 KRW · Dividend yield 4.0% · Net margin 12.7% · Return on equity 9.3% · Return on assets (EBIT) 11.1% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 53 out of 100 (low confidence).
What moves the price
The share trades about 20% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 103%, 023910 screens cheaper than that median.
Fair Value models
Bear31,969 KRWFair Value 50,134 KRWBull74,270 KRW
Price 24,700 KRW · Upside +103.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (3,157 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.53/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+2.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.7%
Start year 2020 (pandemic). Over 10 years: +5.3% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+8.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+4.5%
Dividend (yield on the price)4.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.4.5% vs 4.8%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.18% → 15%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+55.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +51.8% a year for the price.
Compare Daihan Pharmaceutical Co.Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 11/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score53 · Below median
Fair Value upside+103.0% · Top 25%
Profitability
Return on equity (12 months)9.3% · Above median
Return on assets8.0% · Above median
Net margin (12 months)12.7% · Above median
Operating margin (12 months)14.3% · Above median
Growth and dividend
Revenue growth (quarter YoY)9.9% · Above median
Dividend yield (12 months)4.0% · Top 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Daihan Pharmaceutical Co.Ltd (023910) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 50,134 KRW versus a price of 24,700 KRW, about +103% upside (undervalued).
What is the fair value of 023910?
Our model-based fair value for Daihan Pharmaceutical Co.Ltd is 50,134 KRW (as of Nov 8, 2026), built from audited fundamentals. The current price: 24,700 KRW.
What is the quality score of 023910?
Daihan Pharmaceutical Co.Ltd has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Daihan Pharmaceutical Co.Ltd (023910)?
Our model-based price target is the fair value of 50,134 KRW (as of Nov 8, 2026) from 23 valuation models. Cautious scenario 31,969 KRW, optimistic scenario 74,270 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Daihan Pharmaceutical Co.Ltd stock forecast for 2026?
Our models put fair value at 50,134 KRW, about +103% upside versus a price of 24,700 KRW (undervalued). Cautious scenario 31,969 KRW, optimistic scenario 74,270 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Daihan Pharmaceutical Co.Ltd (023910)?
Daihan Pharmaceutical Co.Ltd reported trailing-twelve-month revenue of about 217B KRW (latest available figure, as of Nov 8, 2026).
Does Daihan Pharmaceutical Co.Ltd pay a dividend?
Daihan Pharmaceutical Co.Ltd currently shows a dividend yield of 4.05% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Daihan Pharmaceutical Co.Ltd (023910) and when is the ex-dividend date?
Daihan Pharmaceutical Co.Ltd pays a dividend of 1,000 KRW per share a year, a dividend yield of 4.0%. The last ex-dividend date was Dec 29, 2025. A dividend has been paid every year since at least 2001. The payout ratio is 21.4% of earnings. Free cash flow covers the dividend 0.08 times. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What growth is priced into Daihan Pharmaceutical Co.Ltd (023910)?
For today's price to be fair in a discounted-cash-flow model, Daihan Pharmaceutical Co.Ltd would have to grow free cash flow by +55.0 % per year for five years (discount rate 11.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +4.7 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of 023910 use?
Our models discount Daihan Pharmaceutical Co.Ltd at 11.6 %: a base by market capitalisation (micro), damped by beta 0.15, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Daihan Pharmaceutical Co.Ltd that is +55.0 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.6 %) and the same formula as our fair value.
How much growth has Daihan Pharmaceutical Co.Ltd (023910) delivered so far?
Over the past 5 years revenue at Daihan Pharmaceutical Co.Ltd grew +4.7 % a year. The price currently implies free-cash-flow growth of +55.0 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Daihan Pharmaceutical Co.Ltd (023910) growing?
The median revenue growth in the sector is +14.3 % a year. That is the yardstick for the growth priced into Daihan Pharmaceutical Co.Ltd (+55.0 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Daihan Pharmaceutical Co.Ltd (023910)?
The free-cash-flow yield on the price is 0.33 %: that much free cash flow Daihan Pharmaceutical Co.Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Daihan Pharmaceutical Co.Ltd (023910)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Daihan Pharmaceutical Co.Ltd it is 50,134 KRW per share (as of Nov 8, 2026), against a price of 24,700 KRW. It is the blended result of 23 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Daihan Pharmaceutical Co.Ltd stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 023910 trades below its calculated fair value: price 24,700 KRW, fair value 50,134 KRW, a gap of about +103% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 023910?
No. The price is what the market pays today (24,700 KRW); the fair value is what the company's own numbers justify (50,134 KRW). For Daihan Pharmaceutical Co.Ltd the two are 25,434 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Daihan Pharmaceutical Co.Ltd worth?
The market values Daihan Pharmaceutical Co.Ltd at about 145B KRW (market capitalisation, as of Nov 8, 2026). Per share that is 24,700 KRW; our models calculate a fair value of 50,134 KRW per share.
What do the bullish and bearish scenarios say about 023910?
Our models span a range for Daihan Pharmaceutical Co.Ltd: cautious scenario 31,969 KRW, base 50,134 KRW, optimistic 74,270 KRW per share (as of Nov 8, 2026, price 24,700 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 023910?
Daihan Pharmaceutical Co.Ltd trades at a price-to-earnings ratio of 5.3 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 50,134 KRW is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings, FY2025 ex one-offs: 7.5. Other multiples: P/B 0.5, P/S 0.7, EV/EBITDA 2.4.
How solid is the balance sheet of Daihan Pharmaceutical Co.Ltd (023910)?
Balance-sheet figures for Daihan Pharmaceutical Co.Ltd (as of Nov 8, 2026): return on equity 9.3%. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is 023910 from its 52-week high?
Daihan Pharmaceutical Co.Ltd trades at 24,700 KRW, about 20% below its 52-week high of 30,950 KRW and 1% above the low of 24,350 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 50,134 KRW is for.
Which stocks are comparable to Daihan Pharmaceutical Co.Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Daihan Pharmaceutical Co.Ltd stock attractive at the current price?
The data as of Nov 8, 2026: price 24,700 KRW, calculated fair value 50,134 KRW (+103%), Quality Score 53/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 023910 calculated?
We run Daihan Pharmaceutical Co.Ltd through 23 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 50,134 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Daihan Pharmaceutical Co.Ltd currently trades 51% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Daihan Pharmaceutical Co.Ltd (023910)?
The closing price on Nov 6, 2026 was 24,700 KRW. Our model-based fair value is 50,134 KRW, about +103% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Daihan Pharmaceutical Co.Ltd right now?
The price is below even our cautious bear case (31,969 KRW). The market is more pessimistic than our downside scenario. Solid quality (53/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (31,969 KRW to 74,270 KRW) leaves room in how you read the outcome.
Key figures of Daihan Pharmaceutical Co.Ltd
How large is the market capitalisation of Daihan Pharmaceutical Co.Ltd (023910)?
The market capitalisation of Daihan Pharmaceutical Co.Ltd is 145B KRW (≈ $107M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Daihan Pharmaceutical Co.Ltd (023910)?
The price-to-sales ratio of Daihan Pharmaceutical Co.Ltd is 0.67 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Daihan Pharmaceutical Co.Ltd (023910)?
Earnings per share at Daihan Pharmaceutical Co.Ltd are 4,682 KRW (price ÷ EPS = P/E 5.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Daihan Pharmaceutical Co.Ltd (023910)?
The dividend yield of Daihan Pharmaceutical Co.Ltd is 4.0% (payout 21.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Daihan Pharmaceutical Co.Ltd (023910)?
The net margin of Daihan Pharmaceutical Co.Ltd is 12.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Daihan Pharmaceutical Co.Ltd (023910)?
The return on equity (ROE) of Daihan Pharmaceutical Co.Ltd is 9.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Daihan Pharmaceutical Co.Ltd (023910)?
On an EBIT basis the return on assets of Daihan Pharmaceutical Co.Ltd is 11.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Daihan Pharmaceutical Co.Ltd (023910)?
The operating margin of Daihan Pharmaceutical Co.Ltd is 14.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Daihan Pharmaceutical Co.Ltd (023910)?
Revenue at Daihan Pharmaceutical Co.Ltd is growing +9.9% versus a year earlier (3y avg +4.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Daihan Pharmaceutical Co.Ltd (023910)?
Earnings per share at Daihan Pharmaceutical Co.Ltd are growing +8.9% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Daihan Pharmaceutical Co.Ltd in the live analysis
One click puts Daihan Pharmaceutical Co.Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 8, 2026